share_log

Masimo Provides Leadership And Business Updates; Appoints Michelle Brennan As Interim CEO Following Joe Kiani's Decision To Resign, Reaffirms Financial Guidance For Q3 2024

Masimo Provides Leadership And Business Updates; Appoints Michelle Brennan As Interim CEO Following Joe Kiani's Decision To Resign, Reaffirms Financial Guidance For Q3 2024

麥斯莫醫療提供領導力和業務更新;宣佈米歇爾·布倫南(Michelle Brennan)接任臨時CEO,繼喬·基亞尼(Joe Kiani)辭職之後,重申2024年第三季度的財務指引。
Benzinga ·  09/25 21:10

Appoints Michelle Brennan as Interim CEO Following Joe Kiani's Decision to Resign

根據喬·基亞尼決定辭職,任命米歇爾·布倫南爲代理首席執行官

Continues to Be Committed to Review of Strategic Alternatives for Consumer Businesses, With Assistance From Leading Financial and Legal Advisors

繼續致力於與領先的金融和法律顧問協助下,審查消費業務的戰略選擇

Reaffirms Financial Guidance for Third Quarter 2024

重申2024年第三季度的財務指導

Today the Board of Directors (the "Board") of Masimo (NASDAQ:MASI) a leading global medical innovator, provided a series of leadership and business updates:

今天,納斯達克(MASI)領先全球醫療創新者麥斯莫董事會提供了一系列領導和業務更新:

Leadership Appointments

領導任命

Michelle Brennan, a current member of Masimo's Board, has been appointed interim Chief Executive Officer ("CEO") following Chairman and CEO Joe Kiani informing the Board of his decision to resign as CEO. After being elected by shareholders at the recent Annual Meeting, Darlene Solomon and Bill Jellison have been officially appointed to the Board. These changes are all effective immediately.

米歇爾·布倫南,麥斯莫董事會現任成員,已被任命爲代理首席執行官,在主席兼首席執行官喬·奇亞尼告知董事會決定辭職後。在最近一次年度股東大會上被股東選爲董事會成員後,達琳·所羅門和比爾·傑利森已正式被任命爲董事會成員。這些變化立即生效。

The Board has retained nationally recognized search firm Korn Ferry to assist in CEO succession planning.

董事會已聘請國內知名的尋訪公司光輝國際諮詢顧問協助首席執行官繼任計劃。

Ms. Brennan was elected to the Board in 2023, and previously served as a senior executive at Johnson & Johnson ("J&J") for more than 30 years, where she oversaw medical device businesses globally as well as consumer pharmaceutical businesses. At J&J, Michelle successfully scaled multiple businesses to achieve market-leading growth and led efforts to invest in innovation that resulted in successful new product launches.

布倫南女士於2023年當選爲董事會成員,此前在強生(J&J)擔任高級執行官超過30年,在那裏她全球管理醫療器械業務以及消費藥品業務。在強生,米歇爾成功擴大了多個業務以實現市場領先增長,領導了投資創新的努力,推動成功的新產品推出。

Ms. Brennan commented:

布倫南女士發表意見:

"I am grateful for the trust of the Board and excited by the opportunity to help Masimo continue to grow and lead as an innovation-focused company. As we go through this transition, the Board and management team are excited to learn from and work with our employees, while focusing on ensuring seamless service and support for our customers."

「感謝董事會的信任,對幫助麥斯莫繼續增長和引領作爲一個以創新爲中心的公司的機會感到興奮。在這個過渡期間,董事會和管理團隊很高興能夠向我們的員工學習並與他們合作,同時專注於確保給我們的客戶提供無縫的服務和支持。」

Consumer Business Review

消費業務審查

The Board remains committed to the previously announced review of alternatives for both the consumer audio and consumer healthcare businesses. The Board has engaged Centerview Partners and Morgan Stanley as financial advisors and Sullivan & Cromwell as a legal advisor. The Board looks forward to providing updates in the near-term regarding value-creation initiatives, including this strategic review.

董事會一直致力於之前宣佈的對消費音頻和消費保健業務的替代方案審查。董事會委託Centerview Partners和摩根士丹利擔任財務顧問,Sullivan & Cromwell擔任法律顧問。董事會期待在短期內就包括此戰略審查在內的價值創造倡議提供更新。

Reaffirming Guidance

重申指引

For the third quarter of 2024, Masimo is reiterating its non-GAAP financial guidance previously provided on August 6, 2024. Masimo's previous guidance can be found here.

對於2024年第三季度,麥斯莫重申了之前於2024年8月6日提供的非GAAP財務指引。麥斯莫先前的指引可以在這裏找到。

Chief Financial Officer Micah Young and Chief Operating Officer Bilal Muhsin, added:

致富金融官Micah Young和首席運營官Bilal Muhsin補充道:

"We are excited about the strong momentum of the business and its future prospects for growth. We look forward to providing more details on the upcoming third quarter earnings call next month."

「我們對業務的強勁勢頭和未來增長前景感到興奮。我們期待在下個月即將舉行的第三季度業績會上提供更多細節。」

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論